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Abstract
Importance—Symptomatic adverse events (AEs) in cancer trials are currently reported by 
clinicians using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE). To integrate the patient perspective, the NCI developed a patient-reported 
outcomes version of the CTCAE (PRO-CTCAE) to capture symptomatic AEs directly from 
patients.
Objective—To assess the construct validity, test-retest reliability, and responsiveness of PRO-
CTCAE items.
Design—Participants completed PRO-CTCAE items on tablet computers in clinic waiting rooms 
at two visits 1-6 weeks apart. A subset completed PRO-CTCAE items during an additional visit 
one business day after the first visit.
Setting—Nine U.S. cancer centers and community oncology practices.
Participants—975 adult cancer patients undergoing outpatient chemotherapy and/or radiation 
enrolled between January 2011 and February 2012. Eligibility required participants to read 
English and be without clinically significant cognitive impairment.
Main Outcome(s) and Measure(s)—Primary comparators were clinician-reported Eastern 
Cooperative Oncology Group Performance Status (ECOG PS) and the European Organisation for 
Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30).
Results—940/975 (96%) and 852/940 (91%) participants completed PRO-CTCAE items at each 
visit. 938/940 (99.8%) participants (53% female, median age 59, 32% high school education or 
less, 17% ECOG PS 2-4) reported having at least one symptom. All PRO-CTCAE items had at 
least one correlation in the expected direction with a QLQ-C30 scale (111/124 P<.05). Stronger 
correlations were seen between PRO-CTCAE items and conceptually-related QLQ-C30 domains. 
Scores for 94/124 PRO-CTCAE items were higher in the ECOG PS 2-4 versus 0-1 group (58/124 
P<.05). Overall, 119/124 items met at least one construct validity criterion. Test-retest reliability 
was acceptable for 36/49 pre-specified items (median intra-class correlation coefficient .76; range .
53-.96). Correlations between PRO-CTCAE item changes and corresponding QLQ-C30 scale 
changes reached statistical significance for 27 pre-specified items (median r=.43, range .10-.56; all 
P≤.006).
Conclusions and Relevance—Evidence demonstrates favorable validity, reliability, and 
responsiveness of PRO-CTCAE in a large, heterogeneous U.S. sample of patients undergoing 
cancer treatment. Studies evaluating other measurement properties of PRO-CTCAE are underway 
to inform further development of PRO-CTCAE and its inclusion in cancer trials.
Introduction
In cancer clinical trials, adverse events (AEs) are collected and reported using the U.S. 
National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events 
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(CTCAE).1 The CTCAE is a library of items representing 790 discrete AEs, each graded 
using an ordinal severity scale.2 Approximately 10% of AEs in the CTCAE are symptoms 
(e.g., nausea, sensory neuropathy), which in trials have historically been reported by clinical 
investigators.3 However, there is empiric evidence that collection of this information directly 
from patients improves the precision and reliability of symptomatic AE detection in trials,4-9 
and is feasible.10,11 Moreover, there is substantial evidence that clinical investigators may 
miss up to half of patients' symptomatic AEs.5,6,12,13
To improve precision and patient-centeredness in the capture of symptomatic AEs, the NCI 
developed a library of patient-reported outcome (PRO) items to supplement the CTCAE, 
called the PRO-CTCAE,14 as has been previously described.15 Of the 790 AEs in the 
CTCAE, 78 were identified as amenable to patient self-report. For each of these AEs, PRO 
items were created reflecting the attributes of frequency, severity, interference with usual or 
daily activities, amount, or presence/absence. One to three attributes were selected for any 
given AE depending on the content of the CTCAE criteria for that AE and the nature of that 
particular AE. In total, 124 individual items represent the 78 symptomatic AEs currently in 
the PRO-CTCAE item library.
The generic structure for PRO-CTCAE items and response options are shown in Table 1. 
Each item includes a plain language term for the AE, the attribute of interest, and the 
standard recall period of “the past 7 days”. Cognitive interviews previously determined a 
high level of patient understanding and meaningfulness of the items.16 Software was 
developed for administering PRO-CTCAE items to patients either via web or an automated 
telephone interactive voice response (IVR) interface, and was refined through usability 
testing.15,17
For any new measurement tool in clinical research (e.g., biomarkers, imaging, diagnostic 
test), it is essential to establish that the new instrument accurately and reliably captures the 
underlying phenomenon it is intended to measure. To accomplish this for the PRO-CTCAE, 
this study was designed to evaluate the measurement properties of the 124 items in the PRO-
CTCAE item library including validity (degree to which an instrument accurately measures 
the underlying phenomenon), reliability (ability of an instrument to produce similar scores 
on repeated measurements under similar conditions), and responsiveness (capacity of an 
instrument to show a change when there has been a change in the underlying phenomenon). 
These properties were examined individually for each item since PRO-CTCAE items are 
individually reported in trials and not aggregated into a single score. Inclusion of patients 
with diversity with respect to cancer type, treatment modality, and sociodemographic 
characteristics was considered essential given the intended use of PRO-CTCAE across 
varying research contexts. To simultaneously evaluate the measurement properties of 124 
items within a single study required us to employ a varied set of comparators or “anchors”, 
and warranted a larger and more diverse sample of respondents and settings than is typically 
employed in most validation studies of fixed length PRO measures.
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Adult patients initiating or undergoing outpatient chemotherapy, radiation, or both at one of 
nine U.S. cancer centers or community oncology practices were approached in clinical 
waiting areas and invited to participate in this study. Participating sites with number of 
patients enrolled included Dana-Farber Cancer Institute, Boston, MA (N=40); Hartford 
Hospital-Helen and Harry Gray Cancer Center, Hartford, CT (N=104); Helen F. Graham 
Cancer Center & Research Institute at Christiana Care Health System, Newark, DE 
(N=105); Mayo Clinic, Rochester, MN (N=9); Memorial Sloan Kettering Cancer Center, 
New York, NY (N=280); Our Lady of the Lake and Mary Bird Perkins Cancer Center, Baton 
Rouge, LA (N=133); Gibbs Cancer Center, Spartanburg, SC (N=113); St. Joseph Hospital of 
Orange, Orange, CA (N=104); and University of Texas M. D. Anderson Cancer Center, 
Houston, TX (N=52).
Eligibility criteria required that all participants be able to read and comprehend English, be 
without clinically significant cognitive impairment based on site investigator judgment, have 
a cancer diagnosis, and be actively undergoing cancer treatment or be initiating treatment in 
the next 7 days. Patients with any cancer type were eligible, but an accrual strategy was used 
to enrich for specific cancer types in order to facilitate planned comparisons between groups 
based on cancer type in the validity analysis, including breast; aerodigestive tract (head/neck 
and esophageal cancer); genitourinary (prostate and bladder); lung; colorectal; and 
lymphoma/myeloma. An enrichment strategy was also employed to ensure that a minimum 
of 15% of participants had impaired performance status (PS) defined as Eastern Cooperative 
Oncology Group (ECOG) PS ≥2.
Study sites were selected to encompass geographic, racial/ethnic, economic, and educational 
diversity reflective of the U.S. population with the understanding that the requirement to be 
English speaking would limit the enrollment of Hispanic patients (a separate study 
evaluating the Spanish language version of the PRO-CTCAE has been conducted18). Race/
ethnicity was self-reported by patients.
Institutional review board approval was obtained at all sites and at the NCI, and all patients 
completed written informed consent. The trial was registered on ClincialTrials.gov 
(NCT02158637). Each participant received a $20 gift card or parking voucher.
Questionnaire
The previously developed PRO-CTCAE item library consists of 78 symptomatic AEs 
represented by 124 distinct items.14,15 To limit burden, a maximum of 58 symptomatic AEs 
(82 items) was presented to each participant. Seven electronic surveys targeted towards 
different cancer types (eTable 1) were created in the central PRO-CTCAE web survey 
administration platform. As part of the registration process, the site coordinator selected a 
single survey based on the patient's diagnosis, and that survey was then automatically 
scheduled for completion at each visit. All surveys included a set of 20 “core” symptomatic 
AEs15, predetermined based on high prevalence across cancer types in prior NCI-sponsored 
clinical trials.19 Remaining symptomatic AEs were classified a priori as likely to be 
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prevalent or non-prevalent in specific cancer types based on expert consultation, patient 
representative input, and literature review. These items were included on surveys for selected 
cancer types to facilitate planned comparisons between groups based on cancer type. When 
80% of accrual was reached, to increase sample size for the 58 symptomatic AEs which 
were not systematically administered to all patients, a new survey containing exactly these 
58 symptomatic AEs was administered to all subsequently enrolled patients.
Procedure
PRO-CTCAE items were completed by participants prior to clinic appointments on tablet 
computers via the PRO-CTCAE measurement system hosted on a secure server at the 
NCI.17 To optimize usability by individuals with disabilities, PRO-CTCAE software is 
compliant with Section 508 of the U.S. Rehabilitation Act. The PRO-CTCAE measurement 
system employs conditional branching for AEs that contain more than a single attribute, 
such that subsequent items about severity or interference are skipped if respondents indicate 
that they are not experiencing a specific symptomatic AE. Participants were required to 
answer questions without assistance, but could request technical assistance with using the 
tablet computer from study staff.
Anchors
Anchors are measurable criteria pre-specified as comparators in an instrument validation 
study. Examples of anchors relevant in PRO validation studies include well-validated 
patient- and clinician-reported outcomes and clinical variables such as disease site or 
concurrent medication use. For this study, anchors selected a priori included both generic 
measures (e.g., patient-reported global health-related quality of life [HRQOL] or clinician-
reported performance status) and more specific clinical variables (e.g., antiemetic use or 
receipt of taxane chemotherapy). These anchors were selected based on literature review, 
expert consensus, and patient representative input.
The PRO anchors were administered to participants using a paper booklet containing the 
European Organisation for Research and Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC QLQ-C30),20 a 30-item instrument which produces a HRQOL 
summary score,21,22 a global health status/quality of life (QOL) scale score, 5 functioning 
(physical, role, emotional, social, cognitive) scale scores, and 9 selected symptom item/scale 
scores. 28 items are measured on a 1-4 scale (1=not at all; 4=very much) with the remaining 
two items (overall health and QOL) scored on a 1-7 scale (1=very poor; 7=excellent). Like 
PRO-CTCAE, the recall period for the QLQ-C30 is “the past week”. Patients also completed 
three Global Impression of Change (GIC)23,24 items at the primary follow-up visit. These 
items asked patients to rate their changes in overall QOL; physical condition; and emotional 
state on a 7-point scale ranging from “very much better”, “moderately better”, “a little 
better”, “about the same”, “a little worse”, “moderately worse”, to “very much worse”.
Clinician-reported ECOG PS was collected at each visit via a case report form. Other 
clinical anchors were abstracted from medical charts and included whether the participant 
had received radiation, surgery, and/or chemotherapy in the prior two weeks; type of 
chemotherapy; and use of specific medication classes, including: hormonal therapy, narcotic 
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analgesics, laxatives/stool softeners, antiemetics, sleep aids, anti-diarrhea medications, 
antacids, bronchodilators/inhaled corticosteroids, anxiolytics, and/or antidepressants.
Study Visits
Participants were assigned to one of three groups with differing questionnaire schedules 
based on cancer type and clinic visit schedule, to avoid the necessity of extra clinic visits in 
this symptomatic population (eFigure 1). Group A included patients undergoing daily 
radiation or chemoradiation to enable analyses of test-retest reliability and varying recall 
periods (recall period analyses will be reported separately).25 Group B included patients 
with at least four planned consecutive weekly clinic visits. Group C included participants 
whose planned clinic visits precluded participation in Group B but who did have a return 
clinic visit planned within 1-6 weeks. Irrespective of group assignment, all patients 
completed PRO-CTCAE items and QLQ-C30 at two visits that were spaced approximately 
1-6 weeks apart. At each visit, ECOG PS and other clinical anchors were recorded on case 
report forms. PRO-CTCAE surveys administered to patients in Group A on the business day 
following study day 1 were used for the analysis of test-retest reliability, and included 49 
pre-specified PRO-CTCAE items.
Statistical analysis
Construct validity reflects the association between a new measurement tool and an 
established measure of the underlying concept(s) of interest. Construct validity is often 
investigated through convergent validity, which determines if the new measure moves in the 
same direction as an established instrument, and known-groups validity, which determines if 
the measurement tool can distinguish between groups of patients who are thought to be 
distinct with respect to the underlying concept being measured. To assess convergent 
validity, Pearson correlations were computed between each PRO-CTCAE item and QLQ-
C30 HRQOL summary and other functioning/symptom scale scores. To aid interpretation, 
QLQ-C30 HRQOL summary and functioning/global scales were reverse scored such that 
higher scores represent inferior outcomes, matching the direction of PRO-CTCAE items. 
Pearson correlation values of .1, .3, and .5 were interpreted as small, medium, and large.26 
To assess known-groups validity, two-sample t-tests for ordinal 0-4 scales and chi-squared 
tests for binary scales were used to compare each PRO-CTCAE item between patients with 
high and low performance status (ECOG PS 0-1 versus 2-4). Additional known-groups 
analyses were pre-specified for PRO-CTCAE items that were expected to be higher in one 
group of patients versus another on the basis of cancer type, treatment, or other clinically 
relevant characteristic (e.g., pain in the abdomen in patients with gastrointestinal versus lung 
cancers). Effect sizes (computed as the difference between group means divided by the 
pooled standard deviation [Cohen's d], or difference between twice the arcsine of the square 
root of each sample proportion [Cohen's h]) of .2, .5, and .8 were interpreted as small, 
medium, and large.26
Test-retest reliability was estimated using the intra-class correlation coefficient (ICC) based 
on a one-way analysis of variance model27 with an ICC of .7 or greater interpreted as 
acceptable.28 Responsiveness of items was investigated by comparing change from first to 
second visit in 27 PRO-CTCAE items selected a priori. Comparisons were made using a 
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one-sided Jonckheere-Terpstra test across respondents who reported their GIC to be worse 
(“a little worse”, “moderately worse”, or “very much worse”), unchanged (“about the 
same”), or improved (“a little better”, “moderately better”, or “very much better”).29 
Standardized response means (SRM) were computed as the mean change score divided by 
the standard deviation of the change scores within each change category (worse versus no 
change versus improved) for each PRO-CTCAE item. Pearson correlations were also 
computed between PRO-CTCAE item changes and QLQ-C30 scale changes. One GIC item 
and one QLQ-C30 scale were specified a priori for each of the 27 PRO-CTCAE items. See 
eTable 2 for symptomatic AEs included in each analysis.
To accommodate conditional branching in the PRO-CTCAE software, values for 
automatically skipped items were assumed to be zero. P-values <.05 were considered 
statistically significant throughout. To take into consideration potential collinearity and 
multiplicity, sensitivity analyses employed a stricter p-value cut-off of <.001 and Hochberg's 
step-up procedure30 across construct validity analyses within each item. An item was 
considered valid if statistical significance (P<.05) along with a meaningful effect size 
(Pearson r≥.1 or group difference effect size d or h≥.2) was observed for at least one 
convergent or known-groups validity analysis.
Results
Between January 2011 and February 2012, 975 patients initiating or undergoing 
chemotherapy and/or radiation were enrolled with 940/975 (96%) eligible patients 
completing PRO-CTCAE items at Visit 1 and 852/940 (91%) completing PRO-CTCAE 
items at Visit 2 (eFigure 1). Characteristics of the 940 participants included in this analysis 
are presented in Table 2. Median age was 59 years (range 19-91), 539 (57%) were female, 
161 (17%) had impaired PS (ECOG 2-4), and 305 (32%) had no more than a high school 
education.
Most participants (938/940 [99.8%]) reported presence of at least one symptom (i.e., a score 
greater than 0) during the two primary visits, with 768/940 (82%) reporting at least one 
symptom as frequent, severe, and/or interfering “quite a bit” with daily activities. Patients 
were broadly symptomatic reporting presence of a median of 23 symptoms (range 0-91) 
with 904/940 (96%) reporting presence of 5 or more symptoms at the first visit. 118/124 
(95%) PRO-CTCAE items were reported as present by at least 10% of respondents at both 
primary visits, with 82/124 (66%) items having at least 25% prevalence. The distribution of 
item scores for the set of 20 “core” symptomatic AEs appears in eFigure 2.
Detailed results related to construct validity of PRO-CTCAE items using all anchors are 
provided in eTable 3. With respect to convergent validity, 122/124 (98%) PRO-CTCAE 
items were associated in the expected direction with the QLQ-C30 HRQOL summary score 
(102/124 P<.05; 87/124 P<.001; Figure 1); 107/124 items demonstrated meaningful 
correlation (Pearson r≥.1). When considering all QLQ-C30 functioning/global scales, 
124/124 (100%) PRO-CTCAE items were associated in the expected direction with one or 
more scales, with 114/124 demonstrating meaningful correlation (Pearson r≥.1), and 
111/124 coefficients reaching statistical significance (P<.05; 90/124 P<.001). PRO-CTCAE 
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items that were likely to impact physical functioning had the strongest correlations with the 
QLQ-C30 physical functioning scale (e.g., shortness of breath severity: Pearson r=.47, P<.
001) whereas items likely to impact cognitive functioning had the strongest correlations with 
the QLQ-C30 cognitive functioning scale (e.g., problems with concentration severity: 
Pearson r=.71, P<.001; problems with memory severity: Pearson r=.69, P<.001). Similar 
results were seen between PRO-CTCAE items and conceptually-related QLQ-C30 
emotional, role, and social functioning scales. For those PRO-CTCAE items with a parallel 
QLQ-C30 symptom scale/item (e.g., fatigue), large correlations between analogous items 
(all Pearson r>.69, P<.001) were consistently observed.
In the known-groups comparison between patients with low and high performance status, 
94/124 PRO-CTCAE items had higher mean scores in the ECOG PS 2-4 group versus 0-1 
group (58/124, P<.05; 37/124, P<.001; shown for 37 PRO-CTCAE items in eFigure 3).
In 127 a priori known-groups comparisons involving 87 PRO-CTCAE items based on cancer 
type, treatment, or other clinically relevant characteristic, 110/127 comparisons 
demonstrated higher PRO-CTCAE scores in the group expected to have worse symptom 
experience (85/127, P<.05; 53/127, P<.001, eTable 3).
Most PRO-CTCAE items (119/124) reached a statistically significant and meaningful effect 
size on one or more construct validity criteria. The five items that did not exhibit at least one 
statistically significant and meaningful effect had low prevalence in this sample, thereby 
limiting our analysis. These items were: nosebleeds (prevalence 14.9% [frequency] and 
14.0% [severity]); pain, swelling or redness at site of drug injection or intravenous therapy 
(prevalence 12.5%); pain during vaginal sex (prevalence 20.7%); and rash (prevalence 
17.5%). A majority of PRO-CTCAE items (99/124 and 101/124) remained statistically 
significant under stricter criteria (P<.001 and Hochberg's P<.05) in sensitivity analyses 
(eTable 3).
In the subset of 80 respondents who completed PRO-CTCAE on consecutive business days 
(median 1 day, range 1-3 days), the test-retest reliability for the 49 pre-specified items 
ranged from .53 to .96 (median ICC .76) with 36/49 items having an ICC ≥.7 (eTable 4).
In the analysis of responsiveness (Figure 2), statistically significant (P<.05) monotonically 
decreasing mean PRO-CTCAE change scores were observed for 23 of 27 pre-specified items 
(P<.001 for 13 items). The median SRM in patients reporting worsening was .19 (range .03-.
40), whereas median SRM in patients reporting improvement was -.14 (range -.30-.09). 
Statistically significant correlations were observed between PRO-CTCAE item changes and 
corresponding QLQ-C30 scale changes for all 27 pre-specified items (median r=.43, range .
10-.56; all P≤.006).
Discussion
This large-scale multicenter study in adults undergoing active cancer therapy provides 
evidence supporting the validity, reliability, and responsiveness of the items in the PRO-
CTCAE library. The PRO-CTCAE is unique in its intended use to complement the CTCAE 
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by providing comprehensive data on symptomatic AEs in cancer clinical trials from the 
patient perspective.
The design of this study posed a unique methodological challenge, due to the goal of 
assessing, within a single investigation, the measurement properties of 124 individual items 
representing a broad spectrum of symptomatic toxicities. Typically, PRO validation studies 
will test the properties of a single composite index score or a small number of domains that 
encompass related concepts. For the assessment of validity in the current study, the primary 
strategy to address this challenge was inclusion of both broad generic anchors (e.g., global 
HRQOL, ECOG PS) and more specific clinical variables (e.g., receipt of specific medication 
classes such as antiemetics). Interestingly, all of the PRO-CTCAE items were associated in 
the expected direction with at least one generic functioning measure, suggesting the impact 
that even a single toxicity may have on the patient experience.
Strengths of this study include the diverse sample, reflecting a wide range of cancer types 
and treatment modalities, and enrichment for less common cancer types. The sample was 
also successfully enriched for patients with impaired performance status (ECOG PS ≥2), 
enabling demonstration of the meaningfulness of PRO-CTCAE among those with 
substantial symptom burdens, as well as the feasibility of survey administration in 
debilitated patients. Moreover, participants were accrued at both academic and community 
sites across the U.S., including rural and urban settings, and reflected a range of educational 
and racial backgrounds.
Several caveats should be considered. First, our study was conducted in an English-speaking 
U.S.-residing patient population. Ongoing research is evaluating linguistic adaptations of 
PRO-CTCAE, and the measurement properties of both the English and other language 
versions in settings outside the U.S.31 Linguistic validation of a Spanish language translation 
of PRO-CTCAE is being reported elsewhere.18 Second, we assessed reliability in a subset of 
49 items; thus, future studies to examine the test-retest reliability of the remaining PRO-
CTCAE items are warranted. Third, a small number of highly specific symptomatic AEs 
were uncommon in the study sample and received low endorsement rates, thus limiting our 
ability to evaluate their measurement properties. Specifically, five items reflecting four 
symptomatic AEs (nosebleeds; pain/swelling/redness at site of drug injection or intravenous 
therapy; pain during vaginal sex; and rash) did not exhibit a statistically significant and 
meaningful effect on at least one construct validity criterion. These items are being evaluated 
in other clinical trial contexts. While the large number of items and anchors evaluated in this 
study raises the possibility of inflated Type I error, in sensitivity analyses using more 
stringent significance thresholds, the majority of items retained statistical significance. 
Lastly, notwithstanding inclusion of diverse malignancies in this study, results may not fully 
generalize to populations with rare tumor types. However, a prior cognitive interviewing 
study16 affirms that PRO-CTCAE items were well understood by respondents with varying 
disease sites and receiving diverse anti-cancer treatments. Continued evaluation of PRO-
CTCAE is currently underway in a variety of trial contexts to support the interpretability and 
value of patient-reporting of symptomatic treatment-related toxicity.
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The CTCAE has historically enabled clinicians to describe the toxicity burden of cancer 
treatments using a consistent standard language allowing comparisons across trials. The 
value of patients' input in describing their own experiences is well recognized. Having a 
measurement system which integrates the patient perspective into AE reporting and which 
fosters consistency, transparency, and comparability across trials is similarly an important 
objective. The results of this validation study suggest that PRO-CTCAE can achieve its 
intended aim of integrating the patient experience into routine clinical trial AE reporting 
thereby augmenting the capacity for informed decision-making. In conclusion, this large-
scale multicenter validation study in individuals undergoing active cancer therapy provides 
robust evidence for the validity, reliability, and responsiveness of items in the PRO-CTCAE 
library.
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• Symptomatic adverse events (AEs) in cancer trials are currently graded by 
clinicians using the National Cancer Institute's (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE)
• This study assessed the measurement properties (validity, reliability, and 
responsiveness) of the newly developed NCI Patient-Reported Outcomes version 
of the CTCAE (PRO-CTCAE)
• A large, heterogeneous sample of 940 adult cancer patients undergoing 
outpatient cancer treatment provided PRO-CTCAE and other patient-reported 
and clinical data
• A majority of the PRO-CTCAE items (119 out of 124) met at least a validity 
criterion
• PRO-CTCAE provides a valid and reliable assessment of symptomatic toxicities 
from the patient's perspective, and is encouraged for use in oncology trials to 
enhance the accuracy of AE reporting
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Figure 1. Pearson Correlations between 124 PRO-CTCAE Item Scores and EORTC QLQ-C30 
HRQOL Summary Score* at Visit 1
Abbreviations: PRO-CTCAE, Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events; EORTC QLQ-C30, European Organisation for 
Research and Treatment of Cancer Core Quality of Life Questionnaire; HRQOL, Health-
related quality of life; CTCAE, Common Terminology Criteria for Adverse Events
*See eTable 3 for all computed Pearson correlations between PRO-CTCAE items and 
EORTC QLQ-C30 functioning, global, and symptom scales.
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Figure 2. Standardized Response Means across 27 PRO-CTCAE Items by Patient-Reported 
Global Impression of Change Category*
Abbreviation: PRO-CTCAE, Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events
*Figure 2 includes 27 frequency, severity, and interference items selected prior to initiation 
of the responsiveness analysis. The set of 20 “core” symptomatic AEs was reviewed and 
symptomatic AEs were selected if they had high potential to be meaningfully related to 
global changes in quality of life, physical condition, and/or emotional state (i.e., the Global 
Impression of Change items which were administered at the second visit). Of the 20 
reviewed symptomatic AEs, 13 were included based on this criterion (see eTable 2). The 
symptomatic AEs which were excluded were felt to be related to initiation or changes in 
specific treatments (dry mouth, problems with tasting food/drink, rash) so may not exhibit 
change in a heterogeneously treated sample of patients; require a longer duration of follow-
up to exhibit change (arm/leg swelling, hair loss); or be related to cognitive condition 
(headache, problems with concentration) which was not assessed in the Global Impression 
of Change items.
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Table 1
PRO-CTCAE Item Formats*
Please think back over the past 7 days: Example
Frequency (25 symptomatic AE terms):
How OFTEN did you have __________?
Never / Rarely / Occasionally / Frequently / Almost constantly
Vomiting
Severity (51 symptomatic AE terms):
What was the SEVERITY of your __________ at its WORST?
None / Mild / Moderate / Severe / Very severe
Pain
Interference (25 symptomatic AE terms):
How much did __________ INTERFERE with your usual or daily activities?
Not at all / A little bit / Somewhat / Quite a bit / Very much
Sudden urges to urinate
Presence (21 symptomatic AE terms):
Did you have any __________?
No / Yes
Unusual darkening of the skin
Amount (2 symptomatic AE terms):
Did you have any __________?
Not at all / A little bit / Somewhat / Quite a bit / Very much
Hair loss
Abbreviations: PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; AE, adverse event
*
See Basch et al.15 for a complete listing of PRO-CTCAE items.



















 Range 19 - 91
Age group
 <30 23 2.5%
 30-64 597 63.5%
 65-74 235 25.0%
 ≥75 85 9.0%
Gender
 Female 539 57.3%
 Male 401 42.7%
Ethnicity
 Hispanic or Latino 56 6.0%
 Not Hispanic or Latino 832 88.5%
 Missing 52 5.5%
Race
 White 675 71.8%
 Black or African American 203 21.6%
 Asian 42 4.5%
 Other or multiple races reported 8 0.9%
 Missing 12 1.3%
Education
 High school or less 305 32.4%
 Some college 199 21.2%
 College graduate or more 415 44.1%
 Missing 21 2.2%
Cancer type
 Lung, head or neck 329 35.0%
 Breast 260 27.7%
 Genitourinary or gynecologic 172 18.3%
 Gastrointestinal 95 10.1%
 Hematologic 47 5.0%
 Other or unknown 37 3.9%
ECOG Performance Status at first visit
 0-1 779 82.9%
 2-4 161 17.1%
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Characteristic No. %




Abbreviation: ECOG, Eastern Cooperative Oncology Group
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